Glucocorticoids Act Directly on Osteoclasts to Increase Their Life Span and Reduce Bone Density
Top Cited Papers
Open Access
- 1 December 2006
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 147 (12) , 5592-5599
- https://doi.org/10.1210/en.2006-0459
Abstract
Glucocorticoid administration to mice results in a rapid loss of bone mineral density due to an imbalance in osteoblast and osteoclast numbers. Whereas excess glucocorticoids reduce both osteoblast and osteoclast precursors, cancellous osteoclast number surprisingly does not decrease as does osteoblast number, presumably due to the ability of glucocorticoids to promote osteoclast life span. Whether glucocorticoids act directly on osteoclasts in vivo to promote their life span and whether this contributes to the rapid loss of bone with glucocorticoid excess remains unknown. To determine the direct effects of glucocorticoids on osteoclasts in vivo, we expressed 11β-hydroxysteroid dehydrogenase type 2, an enzyme that inactivates glucocorticoids, specifically in the osteoclasts of transgenic mice using the tartrate-resistant acid phosphatase promoter. Bone mass, geometry, and histomorphometry were similar in untreated wild-type and transgenic animals. Glucocorticoid administration for 7 d caused equivalent increases in cancellous osteoblast apoptosis, and equivalent decreases in osteoblasts, osteoid, and bone formation, in wild-type and transgenic mice. In contrast, glucocorticoids stimulated expression of the mRNA for calcitonin receptor, an osteoclast product, in wild-type but not transgenic mice. Consistent with the previous finding that glucocorticoids decrease osteoclast precursors and prolong osteoclast life span, glucocorticoids decreased cancellous osteoclast number in the transgenic mice but not wild-type mice. In accord with this decrease in osteoclast number, the loss of bone density observed in wild-type mice was strikingly prevented in transgenic mice. These results demonstrate for the first time that the early, rapid loss of bone caused by glucocorticoid excess results from direct actions on osteoclasts.Keywords
This publication has 25 references indexed in Scilit:
- Glucocorticoids suppress bone formation via the osteoclastJournal of Clinical Investigation, 2006
- 11β-Hydroxysteroid dehydrogenase type 2 and the regulation of surfactant protein A by dexamethasone metabolitesAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Reversal of Bone Loss in Mice by Nongenotropic Signaling of Sex SteroidsScience, 2002
- The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone ResorptionJournal of Bone and Mineral Research, 2000
- Functional Hierarchy between Two OSE2 Elements in the Control of Osteocalcin Gene Expression in VivoJournal of Biological Chemistry, 1998
- Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.Journal of Clinical Investigation, 1998
- Dexamethasone and 11-dehydrodexamethasone as tools to investigate the isozymes of 11β-hydroxysteroid dehydrogenase in vitro and in vivoJournal of Endocrinology, 1997
- Characterization of the mouse tartrate-resistant acid phosphatase (trap) gene promoterJournal of Bone and Mineral Research, 1995
- Glucocorticoid regulation of calcitonin receptor in mouse osteoclast-like multinucleated cellsJournal of Bone and Mineral Research, 1994
- Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committeeJournal of Bone and Mineral Research, 1987